These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22109829)

  • 1. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
    Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter.
    Dumont AG; Reynoso DG; Trent JC
    Cancer Res; 2011 Mar; 71(6):2403; author reply 2404. PubMed ID: 21406406
    [No Abstract]   [Full Text] [Related]  

  • 6. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
    Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
    Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
    Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
    PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
    Yang Y; Li XQ; Huang Q; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):594-7. PubMed ID: 21729530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
    Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
    Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
    [No Abstract]   [Full Text] [Related]  

  • 11. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
    Gao XN; Lin J; Li YH; Gao L; Wang XR; Wang W; Kang HY; Yan GT; Wang LL; Yu L
    Oncogene; 2011 Aug; 30(31):3416-28. PubMed ID: 21399664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
    Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
    J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
    Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
    Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
    Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
    Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
    Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
    Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
    Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
    Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
    Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.